

ENDURING MATERIAL LEARNER NOTIFICATION

AACT/ABAT Journal Club April 2021: The physio-stigma enigma, what's the "DRYL"?

Date of CE Release: April 6, 2021

Date of CE Expiration: April 6, 2022

Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians and Pharmacists



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™* for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives - After attending this program you should be able to:

1. Describe the adverse effects associated with physostigmine administration.
2. Describe the effectiveness of physostigmine in treating anticholinergic delirium in diphenhydramine ingestions.
3. Appraise the utility of physostigmine compared to benzodiazepines for the acute management of patients with antimuscarinic delirium and agitation.
4. Describe the safety and efficacy of a physostigmine bolus and infusion for the control of antimuscarinic delirium and agitation.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Role in Activity	Commercial Interest
Serena	Huntington	Speaker	Nothing to disclose
Varun	Vohra	Speaker	Nothing to disclose
Michele	Kanter	Moderator/Organizer	Nothing to disclose
Sharon	Ternullo	Moderator/Organizer	Nothing to disclose
Alexandra	Funk	Moderator/Organizer	Nothing to disclose
Kirk	Cumpston	CME Committee Chair	Nothing to disclose
Victoria	Cooper	AACT Admin	Nothing to disclose

How to Get Your Certificate:

1. Go to <http://aact.cmecertificateonline.com>
2. Click on the "AACT/ABAT Journal Club April 2021: The physio-stigma enigma, what's the "DRYL"?" link.

Please print all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com